Statements (64)
Predicate | Object |
---|---|
gptkbp:instanceOf |
chemical compound
|
gptkbp:chemicalFormula |
C12H15N3O2
|
gptkbp:hasAccessibilityFeatures |
high
|
gptkbp:hasAwards |
specific receptor
|
gptkbp:hasCharacter |
Phase II
|
gptkbp:hasFacility |
soluble in water
|
gptkbp:hasFilm |
nausea
|
gptkbp:hasMerchandise |
inhibits enzyme Y
|
gptkbp:hasMission |
chronic pain
|
gptkbp:hasPopulation |
adults
|
gptkbp:hasPrograms |
low toxicity
|
gptkbp:hasWeight |
233.27 g/mol
|
https://www.w3.org/2000/01/rdf-schema#label |
WME-107
|
gptkbp:isAssociatedWith |
receptor Z
|
gptkbp:isAttendedBy |
hospital settings
oral route clinical settings clinical trial participants patients with condition Y |
gptkbp:isAvailableIn |
tablet
|
gptkbp:isCompatibleWith |
stable at room temperature
|
gptkbp:isDocumentedIn |
clinical guidelines
research publications clinical trial registries |
gptkbp:isEvaluatedBy |
patient outcomes
safety and efficacy long-term effects quality of life improvements efficacy in pain management |
gptkbp:isFundedBy |
gptkb:ABC_Labs
|
gptkbp:isInformedBy |
excipients A and B
|
gptkbp:isPartOf |
research studies
clinical trials alternative therapies treatment guidelines therapeutic regimen therapeutic protocols drug development pipeline standard treatment WME-106 |
gptkbp:isPortrayedBy |
clinical research
scientific literature medical journals |
gptkbp:isRegulatedBy |
gptkb:FDA
|
gptkbp:isRelatedTo |
WME-108
|
gptkbp:isStudiedIn |
various demographics
Phase III trials efficacy in various conditions WME-109 efficacy in specific populations treatment of disease X |
gptkbp:isTrainedIn |
placebo
|
gptkbp:isUsedBy |
healthcare_professionals
|
gptkbp:isUsedIn |
medical research
experimental treatments |
gptkbp:isUtilizedFor |
autoimmune diseases
chronic conditions pain relief neurological disorders |
gptkbp:isUtilizedIn |
preclinical studies
|
gptkbp:isVisitedBy |
gptkb:XYZ_Pharmaceuticals
|
gptkbp:notableArtists |
cancer therapy
|
gptkbp:numberOfFigures |
123456-78-9
|
gptkbp:route |
intravenous
|